Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.63 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.46 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxirane SCHEMBL27976841 | 0.92 | KEAP1 (0.54) | KEAP1LTA4HHSPA5ALOX5MEN1 | |
| SCHEMBL28251912 | 0.86 | LTA4H (0.72) | LTA4HMEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL2027109 | 0.84 | LTA4H (0.69) | LTA4HMEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL9776607 | 0.84 | KEAP1 (0.86) | KEAP1HSPA5ALOX5MEN1KMT2A | |
| SCHEMBL30616875 | 0.84 | KEAP1 (0.86) | KEAP1HSPA5ALOX5MEN1KMT2A | |
| SCHEMBL994168 | 0.84 | ABCB1 (0.56) | LTA4HSLC5A1SLC5A2CALM1NPC1 | |
| SCHEMBL2580611 | 0.82 | KEAP1 (0.59) | KEAP1LTA4HHSPA5MEN1KMT2A | |
| SCHEMBL28849552 | 0.82 | ALOX5 (0.48) | KEAP1LTA4HALOX5MEN1KMT2A | |
| SCHEMBL12869627 | 0.81 | LTA4H (0.60) | LTA4HMEN1KMT2ACYP11B1CYP11B2 | |
| SCHEMBL2580796 | 0.81 | IGF1R (0.53) | LTA4HMEN1KMT2ATDP1CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3315124-B1 | BILAYER TABLET FORMULATIONS | ASTRAZENECA AB (SE) | 2021-01-06 | — | — | EP | disclosed |
| EP-2498759-B1 | IMMEDIATE RELEASE TABLET FORMULATIONS | ASTRAZENECA AB (SE) | 2018-08-01 | — | — | EP | disclosed |
| EP-2714636-B9 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | TFCHEM (FR) | 2017-03-22 | — | — | EP | disclosed |
| US-9434670-B2 | Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars | TFCHEM (FR) | 2016-09-06 | — | — | US | disclosed |
| US-9434670-B2 | Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars | TFCHEM (FR) | 2016-09-06 | — | — | US | disclosed |
| EP-2714636-B1 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | TFCHEM (FR) | 2015-12-16 | — | — | EP | disclosed |
| WO-2015150299-A2 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015110402-A1 | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015091313-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2015-06-25 | — | — | WO | disclosed |
| WO-2014161836-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-10-09 | — | — | WO | disclosed |
| US-20040018998-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-29 | — | — | US | disclosed |
| CN-1466590-A | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | ����ҩƷ��ҵ��ʽ���� | 2004-01-07 | — | — | CN | disclosed |
| EP-1329456-A1 | GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-1313560-A1 | CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION | YALE UNIVERSITY (US) | 2003-05-28 | — | — | EP | disclosed |
| CN-1418219-A | Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the prepararation of the derivatives | KISSEI PHARMACEUTICAL (JP) | 2003-05-14 | — | — | CN | disclosed |
| US-6562989-B2 | Bicyclopentyl iron ligand and transition metal catalyst | YALE UNIVERSITY | 2003-05-13 | — | — | US | disclosed |
| US-20030008768-A1 | Catalyst for aromatic C-O, C-N, and C-C bond formation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| EP-1270584-A1 | GLUCOPYRANOSYLOXY BENZYLBENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES FOR THE PREPARATION OF THE DERIVATIVES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002011883-A1 | CATALYST FOR AROMATIC C-O, C-N, and C-C BOND FORMATION | YALE UNIVERSITY (US) | 2002-02-14 | — | — | WO | disclosed |
| US-4562211-A | ANTIDEPRESSANTS | MITSUBISHI CHEMICAL INDUSTRIES, LTD. (JP) | 1985-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040018998-A1 | Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same | SLC5A2, SLC5A1, SLC2A1 | KEAP1 720/4885LTA4H 1822/4885HSPA5 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.